医学
内科学
危险系数
伊立替康
安慰剂
养生
化疗方案
性能状态
癌症
紫杉烷
胃肠病学
外科
肿瘤科
结直肠癌
置信区间
乳腺癌
病理
替代医学
作者
Josep M. Tabernero,Kohei Shitara,Mikhail Vladimirovich Dvorkin,Wasat Mansoor,Hendrik‐Tobias Arkenau,Aliaksandr Prokharau,María Alsina,Michele Ghidini,Catia Faustino,В. А. Горбунова,Edvard A. Zhavrid,Kazuhiro Nishikawa,A. Hosokawa,D. Ganea,Şuayib Yalçın,Kazumasa Fujitani,Giordano Domenico Beretta,Robert E. Winkler,Lukas Makris,Toshihiko Doi
标识
DOI:10.1093/annonc/mdy208.001
摘要
Background: Trifluridine/tipiracil (FTD/TPI), an orally administered combination agent approved for patients with refractory metastatic colorectal cancer, demonstrated promising clinical activity in a refractory gastric cancer Japanese Phase II trial. Therefore, we initiated the TAGS study (NCT02500043) to evaluate the efficacy and safety of FTD/TPI in patients with heavily pretreated metastatic gastric cancer (mGC).
科研通智能强力驱动
Strongly Powered by AbleSci AI